Symic Biomedical is developing a new category of therapeutics that offer an exciting and biologically innovative approach to treating disease. Symic's compounds function like proteoglycans, important structural and functional macromolecules native to the ECM (extracellular matrix). The ECM is the non-cellular component of tissues that is critical for healthy tissue function.
Market
Therapeutics
Location
San Francisco,
CA,
USA
Coinvestors
Ally Bridge Group, Den Danske Forskningsfond, InCube Ventures, Mission Bay Capital, Mitsui Global Investment, Purdue Foundry Investment Fund, QB3